Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

PJ Online | News: Naltrexone use for alcohol dependence not supported

Home > PJ > News / Daily News

Return to PJ Online Home Page

The Pharmaceutical Journal Vol 267 No 7178 p839-846
15 December 2001

This article
Reprint
Photocopy


News summary


Naltrexone use for alcohol dependence not supported

New data do not support the use of naltrexone, as an adjunct to psychosocial treatment, for the treatment of men with chronic, severe alcohol dependence, American researchers say. Naltrexone, an opioid-receptor antagonist, has been approved for the treatment of alcohol dependence in the United States by the Food and Drug Administration.

Dr John Krystal, Department of Veterans Affairs Alcohol Research Centre, West Haven, Connecticut, and colleagues randomly assigned 627 veterans (mainly men) with chronic, severe alcohol dependence to one of three treatment groups: naltrexone once daily for 12 months; naltrexone once daily for three months followed by placebo for nine months; or placebo for 12 months. Patients receiving naltrexone started with a dose of 25mg once daily for two days and then 50mg once daily for the remainder of the assigned treatment period.

Compared with placebo, naltrexone did not prevent or delay relapse to heavy drinking. It also did not reduce the number of drinking days or decrease the amount of alcohol consumed during episodes of drinking. The researchers conclude that their data raise doubts about the current use of naltrexone for patients with chronic, severe alcohol dependence. However, they add: "Our findings do not rule out the possibility that naltrexone in combination with other medications or with other types of psychosocial interventions, or in other patient groups, may have a role in the treatment of alcoholism" (The New England Journal of Medicine 2001;345:1734).

A spokeswoman for Bristol-Myers Squibb Pharmaceuticals told The Journal that naltrexone is licensed in 14 European countries for the treatment of alcohol dependency, under the trade name ReVia. However, there are no plans for the company to submit an application for such a licence in the United Kingdom.

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20005663

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.